358
Participants
Start Date
September 30, 2024
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
TQB2450+Anlotinib
"TQB2450 injection test group, 1200 mg/time, strength: 600mg/20 mL, intravenous drip, day 1, every 3 weeks. Anlotinib hydrochloride capsules: 8 mg/time, strength: 10mg/capsule, 8mg/capsule, 6mg/capsule., 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.~TQB2450 Injection Placebo (control group): 0 mg/time, strength: 0mg/20 mL, Intravenous Drip, Day 1, every 3 weeks. Anlotinib hydrochloride capsule placebo: 0 mg/time, strength: 0mg/capsule, 1 time a day (QD), continuous use for 2 weeks and stop for 1 week."
TQB2450 placebo + Anlotinib placebo
No drug substance is contained
Anhui Provincial Hospital, Hefei
Tangshan People's Hospital, Tangshan
Beijing Chest Hospital, Capital Medical University, Beijing
The First Hospital of China Medical University, Shenyang
Harbin Medical University cancer hospital, Harbin
Qilu Hospital of Shandong University, Jinan
Shandong Cancer Hospital, Jinan
Zhejiang Cancer Hospital, Hangzhou
Hunan Cancer Hospital, Changsha
Xiangyang Central Hospital, Xiangyang
AnYang Tumor Hospital, Anyang
Guangxi Medical University Cancer Hospital, Nanjing
The Second People's Hospital of Neijiang, Neijiang
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Lanzhou University Second Hospital, Lanzhou
Shanxi Provincial Cancer Hpspital, Taiyuan
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY